What are the indications and coverage of cefoxitin (antibiotic)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefoxitin: Antibiotic Coverage and Indications

Cefoxitin is a second-generation cephalosporin (cephamycin) antibiotic with broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria, indicated for serious infections including intra-abdominal, gynecological, respiratory, skin/soft tissue, bone/joint infections, and septicemia. 1

Antimicrobial Spectrum

  • Effective against gram-positive organisms including Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes 1
  • Active against gram-negative aerobes including Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris, and Providencia species 1, 2
  • Provides excellent coverage against anaerobic bacteria, particularly Bacteroides species (including B. fragilis), Clostridium species, Peptococcus niger, and Peptostreptococcus species 1, 3
  • Notable gaps in coverage include Pseudomonas aeruginosa, Enterobacter species, and enterococci (e.g., Enterococcus faecalis) 1, 2

Clinical Indications

FDA-Approved Indications 1

  • Lower respiratory tract infections (pneumonia, lung abscess)
  • Urinary tract infections
  • Intra-abdominal infections (peritonitis, intra-abdominal abscess)
  • Gynecological infections (endometritis, pelvic cellulitis, pelvic inflammatory disease)
  • Septicemia
  • Bone and joint infections
  • Skin and skin structure infections

Specific Use in Pelvic Inflammatory Disease (PID)

  • Recommended as part of first-line inpatient treatment regimens for PID: cefoxitin 2g IV every 6 hours plus doxycycline 100mg orally/IV every 12 hours 4
  • For outpatient PID treatment: cefoxitin 2g IM with probenecid 1g orally as a single dose, followed by doxycycline 100mg orally twice daily for 14 days 4
  • Important note: Cefoxitin has no activity against Chlamydia trachomatis, requiring addition of doxycycline when treating PID 1

Mixed Aerobic-Anaerobic Infections

  • Particularly valuable for polymicrobial infections involving both aerobic gram-negative rods and anaerobic bacteria 2, 3
  • Can be used as a single-agent alternative to combination therapy (such as cephalosporin plus aminoglycoside) in appropriate mixed infections 2, 5

Dosing Considerations

Intravenous Administration

  • Standard dosing: 2g IV every 6-8 hours for most infections 1
  • For severe infections: up to 12g daily in divided doses 1
  • For PID: 2g IV every 6 hours until clinical improvement (at least 48 hours), then transition to oral therapy 4

Intramuscular Administration

  • 1-2g IM with lidocaine for dilution to reduce injection pain 6
  • For PID outpatient treatment: 2g IM with probenecid 1g orally 4

Clinical Pearls and Caveats

  • Cefoxitin is highly resistant to beta-lactamases, making it effective against many penicillinase-producing organisms 2, 3
  • Treatment failures with cefoxitin are most commonly associated with abscess formation requiring surgical drainage rather than antimicrobial resistance 3, 7
  • When treating PID, cefoxitin must be combined with doxycycline to provide coverage against C. trachomatis 1
  • While cefoxitin has better anaerobic coverage than many cephalosporins, some clinicians add metronidazole for enhanced anaerobic coverage in severe mixed infections 4
  • For post-cesarean infections, cefoxitin may be considered, but other regimens like clindamycin plus gentamicin or ampicillin-sulbactam are also recommended 8

Treatment Duration

  • For most infections: 5-14 days depending on severity and site of infection 1
  • For PID: at least 48 hours of IV therapy after clinical improvement, followed by oral therapy to complete 14 days total 4
  • Patients should demonstrate substantial clinical improvement within 72 hours; if not, reevaluation of diagnosis and treatment is warranted 4

References

Research

Current status of therapy with cefoxitin.

Clinical therapeutics, 1980

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Intramuscular cefoxitin.

Reviews of infectious diseases, 1979

Research

Cefoxitin in treatment of obstetric and gynecologic infections.

Reviews of infectious diseases, 1979

Guideline

Treatment of Post-Cesarean Section Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.